ZEO ScientifiX Inc. · OTC:ZEOX
ZEO ScientifiX — Organicell Regenerative Medicine — Investor Presentation (June 2023)
29 slides from ZEO ScientifiX's investor presentation, Jun 6, 2023
Slide 1: Investor Presentation June 2023
Private And Confidential. © 2023 Organicell Regenerative Medicine, Inc. All rights reserved. Investor Presentation June 2023 1
Slide 2: No Offering of Securities; Forward-Looking Statements
Private And Confidential. © 2023 Organicell Regenerative Medicine, Inc. All rights reserved. No Offering of Securities No offer is made by this Investor Presentation (this "Presentation") to invest in Organicell Regenerative Medicine, Inc .. (the "Company") or to purchase any of its securities . Any
Slide 3: Our Mission
Private And Confidential. © 2023 Organicell Regenerative Medicine, Inc. All rights reserved. Our Mission To transform medicine by developing novel regenerative biologic therapies and nano - technologies to address a broad range of critical medical conditions 3 3
Slide 4: Brief History of Regenerative Medicine
Private And Confidential. © 2023 Organicell Regenerative Medicine, Inc. All rights reserved. Brief History of Regenerative Medicine Definition: Regenerative Medicine replaces or regenerates human cells, tissue or organs, to restore normal function. • Only a few human cell types regenerate naturally
Slide 5: The Regenerative Medicine Market
Private And Confidential. © 2023 Organicell Regenerative Medicine, Inc. All rights reserved. The Regenerative Medicine Market ▪ The global regenerative medicine market has reached $24 billion in 2022. 1 ▪ Projected to reach $180 billion by 2032, expanding at a CAGR of 15.7% from 2023 to 2032. ▪ The
Slide 6: Types of Cellular/Tissue Based Therapies
Private And Confidential. © 2023 Organicell Regenerative Medicine, Inc. All rights reserved. Types of Cellular/Tissue Based Therapies 1. Amniotic fluid - based therapies ( Organicell ) x Technology evaluated since 1910 for safety and efficacy x Tissue processed from human amniotic membrane and fluid
Slide 7: Organicell Snapshot
Private And Confidential. © 2023 Organicell Regenerative Medicine, Inc. All rights reserved. Organicell Snapshot Organicell Regenerative Medicine, Inc. A publicly - traded: (OCEL), clinical - stage biopharmaceutical company committed to the research, development, and manufacture of novel regenerativ
Slide 8: Exosome Basics
Private And Confidential. © 2023 Organicell Regenerative Medicine, Inc. All rights reserved. Exosome Basics ▪ Extracellular vesicles (EVs) are a category of cell - derived membranous structures. ▪ Exosomes are a class of extracellular vesicles released by nearly all cell types: ▪ Present in all body
Slide 9: Organicell Technology Platform
Private And Confidential. © 2023 Organicell Regenerative Medicine, Inc. All rights reserved. Organicell Technology Platform Exosomes are derived from Amniotic Fluid in a proprietary manner ▪ Very high concentrations of exosomes (i.e., billions per milliliter) ▪ Amniotic fluid is immunologically “neu
Slide 10: Product Overview
Private And Confidential. © 2023 Organicell Regenerative Medicine, Inc. All rights reserved. Product Overview x Amniotic Fluid - derived Biologic x Non - HCP/T* x Dose contains approx. 200 billion extracellular vesicles/exosomes x Contains extracellular vesicles, exosomes, bioactive proteins, and hy
Slide 11: In-vitro Cell Culture Testing
Private And Confidential. © 2023 Organicell Regenerative Medicine, Inc. All rights reserved. In - vitro cell culture Testing Zofin Ƴ Inhibits T - cell Activation and Proliferation 1. T - Cells are one of the important white blood cells of the immune system and play a central role in the immune respo
Slide 12: Zofin Exosomes: Pre-Clinical Animal Testing
Private And Confidential. © 2023 Organicell Regenerative Medicine, Inc. All rights reserved. Zofin Ƴ Exosomes: Pre - Clinical Animal Testing Normal Lungs Inflammation of Lungs Inflammation of Lungs After Exosome Treatment Inflammation of Lungs Lungs After Exosome Treatment Organicell Published Data:
Slide 13: Clinical Safety Testing
Private And Confidential. © 2023 Organicell Regenerative Medicine, Inc. All rights reserved. Clinical Safety Testing Organicell Published Data: Proof - of - concept trial of an amniotic fluid - derived extracellular vesicle biologic for treating high risk patients with mild - to - moderate acute COV
Slide 14: Business Plan: Summary
Private And Confidential. © 2023 Organicell Regenerative Medicine, Inc. All rights reserved. Business Plan: Summary Immedia te Revenue Generation ▪ Autologous PPX TM for Musculoskeletal Conditions ▪ Supplier of exosomes & stem cells for clinical trials ▪ Cosmetic partnerships Public Company Events ▪
Slide 15: Understanding Organicell
Private And Confidential. © 2023 Organicell Regenerative Medicine, Inc. All rights reserved. Understanding Organicell Organicell i s comprised of two arms: Clinical Research and Commercial . To monetize our technology and lab assets through the sale of extracellular vesicle and stem cell (ex - US) p
Slide 16: Our Strong Distributor Network
Private And Confidential. © 2023 Organicell Regenerative Medicine, Inc. All rights reserved. Our Strong Distributor Networ k ▪ 8 US Distributors ▪ 2 International Distributors ▪ Partnership with Fountain Life TM 16
Slide 17: Regulatory/FDA Considerations
Private And Confidential. © 2023 Organicell Regenerative Medicine, Inc. All rights reserved. Regulatory/FDA Considerations Current “Safe Harbors” allow immediate commercialization of several product lines that include: 1. Cosmetic applications: ▪ Facial Market, Micro Needling, Hair Restoration, Topi
Slide 18: Laboratory at Nova Southeastern Center for Collaborative Research
Private And Confidential. © 2023 Organicell Regenerative Medicine, Inc. All rights reserved. Laboratory at Nova Southeastern Center for Collaborative Research Current Laboratory Facility State - of - the Art Research and Manufacturing Facility x FDA registered , ISO7, CGMP, & FDA compliant x Quality
Slide 19: Intellectual Property - Patent Update
Private And Confidential. © 2023 Organicell Regenerative Medicine, Inc. All rights reserved. P atent was filed on October 2021 . Awaiting final comments on claims and final approval. Provisional protection filed on October 2022. Filing for a proprietary PPX Ƴ collection kit . Provisional filed on Oc
Slide 20: Valuation of Biopharma Companies
Private And Confidential. © 2023 Organicell Regenerative Medicine, Inc. All rights reserved. Valuation of Biopharma Companies Acquisition Value of 311 Biopharma companies by stage of research from 2005 to 2020* 1. Before a biopharma company has an FDA approved product, company value is typically lin
Slide 21: Key Financial Metrics, Use of Funds, Unit Economics
Private And Confidential. © 2023 Organicell Regenerative Medicine, Inc. All rights reserved. Key Financial Metrics Use of Funds * Unit Economics 21 *$5 million capital raise + $1.8 million from operating funds based on current sales Buildup of New Lab 25% Clinical Trials 18% Operations 14% Debt Repa
Slide 22: Organicell Leadership Team
Private And Confidential. © 2023 Organicell Regenerative Medicine, Inc. All rights reserved. Organicell Leadership Team (see Bios in Appendix) Organicell’s world - class leadership team has broad experience in biotech, commercialization of healthcare products, and managing public healthcare companie
Slide 23: Organicell Medical Advisory Board
Private And Confidential. © 2023 Organicell Regenerative Medicine, Inc. All rights reserved. Organicell Medical Advisory Board Organicell’s distinguished Medical Advisory Board has deep expertise in regenerative medicine, anti - aging therapeutics, and innovative orthopedic solutions Mitchell B. She
Slide 24: Key Investment Considerations
Private And Confidential. © 2023 Organicell Regenerative Medicine, Inc. All rights reserved. Key Investment Considerations x Emerging biotech/commercial company with an advantageous business platform of current revenue streams and diversified clinical trials targeted at accessing large addressable m
Slide 25: Contact
© 2023 Organicell Regenerative Medicine, Inc. All rights reserved. Contact: Harry Leider, MD, MBA 443 - 934 - 4906 [email protected]
Slide 26: Leadership Team Bios: Harry Leider
Private And Confidential. © 2023 Organicell Regenerative Medicine, Inc. All rights reserved. Leadership Team Bios Harry Leider, MD, MBA Chief Executive Officer Harry Leider, MD, MBA joined Organicell as CEO in June of 2023. Dr. Leider, has over 25 years’ experience as a highly successful C - suite h
Slide 27: Leadership Team Bios: Ian T. Bothwell
Private And Confidential. © 2023 Organicell Regenerative Medicine, Inc. All rights reserved. Leadership Team Bios Ian T. Bothwell Chief Financial Officer Ian Bothwell joined Organicell as Chief Financial Officer in 2015. From 2003 through November 2015, Mr. Bothwell served in various executive posit
Slide 28: Leadership Team Bios: Michael A. Bellio
Private And Confidential. © 2023 Organicell Regenerative Medicine, Inc. All rights reserved. Leadership Team Bios Michael A. Bellio , Ph.D Laboratory Director & VP of Research and Manufacturing Dr. Bellio leads the research, development, and manufacturing of novel biological medicine for the treatme
Slide 29: Leadership Team Bios: Ivan Santos
Private And Confidential. © 2023 Organicell Regenerative Medicine, Inc. All rights reserved. Leadership Team Bios Ivan Santos Biologics Manufacturing Operations Manager Ivan Santos is the Biologics Manufacturing and Operations Manager at Organicell . Experienced in regenerative medicine, Ivan has a
Organicell Regenerative Medicine — Investor Presentation (June 2023) on 6ix